CRL Charles River Laboratories International, Inc. Common Stock

NYSE · Life Sciences Tools & Services · SEC EDGAR で表示 ↗
$290.01
株価 · 8月 19, 2026
ファンダメンタルズ(時点) 8月 5, 2026

Charles River Laboratories International, Inc. Common Stock について Wikipediaからの企業概要

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.

続きを読む

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.

Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.

As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.

History

Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.

In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.

The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.

Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.

In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.

In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.

In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.

Acquisitions

In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.

Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.

In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.

In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.

From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.

The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.

In July 2015, the company announced it would acquire Celsis International for $212 million.

In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.

In August 2017, the business announced it would acquire Brains On-Line.

In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.

In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.

In August 2020, the company announced it would acquire Cellero for $38 million in cash.

In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.

In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.

In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.

In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.

In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.

In April 2022, the company announced it would acquire Explora BioLabs.

In January 2023, the business announced it would acquire SAMDI Tech, Inc.

出典: Wikipedia (英語), CC BY-SA 4.0 · Wikipediaで表示 ↗

Wikidata ↗

CRL 株価スナップショット 価格、時価総額、P/E、EPS、ROE、負債/資本、52週レンジ

株価
$290.00
時価総額
$14.27B
P/E (TTM)
-99.7
EPS(TTM)
$-2.91
収益(TTM)
$4.02B
配当利回り
ROE
-4.4%
負債/自己資本
0.0
52週レンジ
$144 – $291

CRL 株価チャート 技術指標付きの日次 OHLCV — パン、ズーム、ビューのカスタマイズ

10年間のパフォーマンス 収益、純利益、利益率、EPSのトレンド

収益と純利益 $4.02B
10-point trend, +138.8%
2016-12-31 2025-12-27
EPS $-2.91
10-point trend, -190.1%
2016-12-31 2025-12-27
フリーキャッシュフロー $518M
10-point trend, +111.6%
2016-12-31 2025-12-27
利益率 -3.6%

バリュエーション P/E、P/S、P/B、EV/EBITDA比率 — 株は割高か割安か?

指標
5年トレンド
CRL
競合中央値
P/E (TTM)
5-point trend, -244.1%
-99.7
39.9
P/S (TTM) (株価売上高倍率(TTM))
5-point trend, -52.6%
3.6
5.6
P/B (株価純資産倍率)
5-point trend, -56.9%
4.5
4.1
EV / EBITDA (EV/EBITDA)
5-point trend, +6.5%
32.8
Price / FCF (株価FCF倍率)
5-point trend, -44.8%
27.5

収益性 粗利益率、営業利益率、純利益率、ROE、ROA、ROIC

指標
5年トレンド
CRL
競合中央値
Operating Margin (営業利益率)
5-point trend, -96.2%
0.63%
Net Profit Margin (純利益率)
5-point trend, -132.5%
-3.6%
11.7%
ROA
5-point trend, -131.5%
-2.0%
4.7%
ROE
5-point trend, -125.9%
-4.4%
8.5%
ROIC
5-point trend, -94.1%
1.1%

財務健全性 負債、流動性、支払能力 — バランスシートの健全性

指標
5年トレンド
CRL
競合中央値
Debt / Equity (負債資本倍率)
5-point trend, +0.00
0.0
15.3
Current Ratio (流動比率)
5-point trend, +4.7%
1.3
1.7
Quick Ratio (クイックレシオ)
5-point trend, -3.9%
0.8

成長 収益、EPS、純利益の成長率:前年比、3年CAGR、5年CAGR

指標
5年トレンド
CRL
競合中央値
Revenue YoY (収益(前年比))
5-point trend, +13.4%
-0.85%
Revenue CAGR 3Y (収益(3年CAGR))
5-point trend, +13.4%
0.33%
Revenue CAGR 5Y (収益(5年CAGR))
5-point trend, +13.4%
6.6%
EPS YoY
5-point trend, -138.3%
-97.8%
Net Income YoY (純利益(前年比))
5-point trend, -136.9%
-95.3%

株当たり指標 EPS、一株当たり純資産、一株当たりキャッシュフロー、一株当たり配当

指標
5年トレンド
CRL
競合中央値
EPS (Diluted) (EPS(希薄化後))
5-point trend, -138.3%
$-2.91

資本効率 総資産回転率、棚卸資産回転率、売掛金回転率

指標
5年トレンド
CRL
競合中央値

CRL アナリストコンセンサス 強気・弱気のアナリストの見解、12ヶ月の目標株価、アップサイド

買い 22 アナリスト
  • 強い買い 5 22.7%
  • 買い 10 45.5%
  • 保有 7 31.8%
  • 売り 0 0.0%
  • 強い売り 0 0.0%

12ヶ月目標株価

14 アナリスト · 2026-08-14
中央値ターゲット $300.00 +3.4%
平均値ターゲット $281.00 -3.1%

決算履歴 EPS実績 vs 予想、サプライズ%、達成率、次回決算日

平均サプライズ
0.21%
期間 EPS Actual EPS 予想 サプライズ
2026年6月30日 $3.02 $2.76 0.26%
2026年3月31日 $2.06 $1.96 0.10%
2025年12月31日 $2.39 $2.37 0.02%
2025年9月30日 $2.43 $2.36 0.07%
2025年6月30日 $3.12 $2.52 0.60%
2025年3月31日 $2.34 $2.10 0.24%

同業他社比較(GICSサブインダストリー) 主要メトリクスとセクターピアの比較

ティッカー 時価総額 P/E 売上高 YoY 純利益率 ROE 粗利益率
CRL $10.02B -70.0 -0.85% -3.6% -4.4%
ILMN $20.65B 24.8 -0.66% 19.6% 34.1% 66.1%
MTD $28.38B 33.2 4.0% 21.6% -615.5% 59.4%
WST $19.81B 40.5 6.2% 16.1% 16.2% 35.9%
MEDP $15.93B 36.8 20.0% 17.8% 142.9%
TEM -41.9 83.4% -19.3% -61.2%
RVTY $10.86B 46.7 3.7% 8.5% 3.3%
TECH $7.97B 111.8 5.2% 6.0% 3.7% 64.8%
TEM -41.9 83.4% -19.3% -61.2%
RGEN $9.23B 190.5 16.4% 6.6% 2.4%
BIO

完全なファンダメンタルズ 年次別全指標 — 損益計算書、貸借対照表、キャッシュフロー

損益計算書 15
CRLの年次損益計算書データ
指標 トレンド 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +209.4% $4.02B $4.05B $4.13B $3.98B $3.54B $2.92B $2.62B $2.27B $1.86B $1.68B $1.36B $1.30B
Cost of Revenue 4-point trend, +8.7% · · · · · · · · $290M $277M $264M $266M
SG&A Expense 12-point trend, +176.2% $743M $751M $748M $665M $620M $529M $518M $444M $371M $365M $300M $269M
Operating Income 12-point trend, -85.8% $25M $227M $617M $651M $590M $433M $351M $331M $288M $238M $206M $178M
Interest Expense 10-point trend, +1044.0% · · $137M $59M $74M $86M $61M $64M $30M $28M $15M $12M
Interest Income 12-point trend, +328.1% $5M $9M $5M $780.0K $652.0K $834.0K $2M $812.0K $690.0K $1M $1M $1M
Other Non-op 12-point trend, -310.6% $-23M $-17M $96M $31M $-36M $100M $12M $13M $38M $12M $3M $11M
Pretax Income 12-point trend, -156.0% $-100M $93M $581M $623M $481M $447M $304M $282M $297M $223M $195M $178M
Income Tax 12-point trend, -10.5% $43M $68M $101M $130M $82M $82M $50M $54M $171M $67M $43M $48M
Net Income 12-point trend, -213.9% $-144M $22M $475M $486M $391M $364M $252M $226M $123M $155M $149M $127M
EPS (Basic) 12-point trend, -207.0% $-2.91 $0.20 $9.27 $9.57 $7.77 $7.35 $5.17 $4.72 $2.60 $3.29 $3.21 $2.72
EPS (Diluted) 12-point trend, -209.4% $-2.91 $0.20 $9.22 $9.48 $7.60 $7.20 $5.07 $4.62 $2.54 $3.23 $3.13 $2.66
Shares (Basic) 12-point trend, +6.3% 49,564,000 51,380,000 51,227,000 50,812,000 50,293,000 49,550,000 48,730,000 47,947,000 47,481,000 47,014,000 46,496,000 46,627,000
Shares (Diluted) 12-point trend, +4.2% 49,564,000 51,628,000 51,451,000 51,301,000 51,425,000 50,611,000 49,693,000 49,018,000 48,564,000 47,958,000 47,634,000 47,558,000
EBITDA 12-point trend, +56.3% $428M $589M $931M $955M $855M $668M $549M $493M $419M $364M $301M $274M
貸借対照表 30
CRLの年次貸借対照表データ
指標 トレンド 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +33.6% $214M $195M $277M $234M $241M $228M $238M $195M $164M $118M $118M $160M
Short-term Investments 7-point trend, -94.8% · · · · $1M $1M $941.0K $885.0K $28M $4M $21M ·
Receivables 12-point trend, +174.8% $709M $721M $780M $752M $643M $618M $514M $472M $430M $364M $270M $258M
Inventory 12-point trend, +235.9% $299M $279M $380M $256M $199M $186M $161M $128M $115M $96M $94M $89M
Prepaid Expense 12-point trend, +185.3% $129M $106M $83M $108M $97M $73M $56M $49M $81M $45M $47M $45M
Other Current Assets 7-point trend, -100.0% · · · · · $0 $300.0K $300.0K $0 $45M $47M $73M
Current Assets 12-point trend, +149.8% $1.45B $1.40B $1.61B $1.44B $1.27B $1.20B $1.02B $898M $827M $657M $559M $579M
PP&E (Net) 12-point trend, +144.6% $1.66B $1.60B $1.64B $1.47B $1.29B $1.12B $1.04B $933M $782M $756M $678M $677M
PP&E (Gross) 12-point trend, +139.7% $3.19B $3.06B $2.98B $2.63B $2.39B $2.21B $2.02B $1.81B $1.58B $1.46B $1.32B $1.33B
Accum. Depreciation 12-point trend, +134.8% $1.54B $1.45B $1.34B $1.16B $1.10B $1.09B $978M $874M $801M $706M $645M $655M
Goodwill 12-point trend, +760.9% $2.76B $2.85B $3.10B $2.85B $2.71B $1.81B $1.54B $1.25B $805M $788M $439M $321M
Intangibles 12-point trend, +21.1% $340M $723M $864M $955M $1.06B $788M $689M $611M $370M $394M $281M $281M
Other Non-current Assets 12-point trend, +301.9% $293M $278M $309M $148M $152M $353M $213M $144M $124M $88M $72M $73M
Total Assets 12-point trend, +281.5% $7.14B $7.53B $8.20B $7.60B $7.02B $5.49B $4.69B $3.86B $2.93B $2.71B $2.07B $1.87B
Accounts Payable 12-point trend, +340.0% $149M $140M $169M $206M $198M $122M $111M $66M $78M $68M $37M $34M
Accrued Liabilities 12-point trend, +300.8% $270M $232M $228M $220M $229M $150M $139M $107M $90M $84M $89M $67M
Current Liabilities 12-point trend, +280.2% $1.12B $994M $1.06B $1.09B $1.03B $840M $710M $558M $464M $430M $312M $295M
Capital Leases 7-point trend, +273.4% $434M $484M $419M $390M $253M $156M $116M · · · · ·
Deferred Tax 12-point trend, +312.4% $95M $107M $191M $216M $240M $217M $167M $144M $90M $56M $48M $23M
Other Non-current Liabilities 12-point trend, +38.9% $138M $195M $223M $175M $243M $205M $183M $179M $195M $159M $89M $100M
Total Liabilities 12-point trend, +236.5% $3.92B $4.02B $4.54B $4.58B $4.43B $3.35B $3.03B $2.52B $1.87B $1.86B $1.30B $1.17B
Long-term Debt 5-point trend, +124.7% · · · · · · · $1.61B $1.09B $1.18B $814M $717M
Total Debt 12-point trend, -100.0% $166.0K $155.0K $3M $1M $101.0K $47M $36M $1.65B $1.12B $1.21B $836M $754M
Common Stock 12-point trend, -41.8% $492.0K $511.0K $513.0K $509.0K $505.0K $498.0K $489.0K $482.0K $875.0K $863.0K $855.0K $845.0K
Retained Earnings 12-point trend, +1100.6% $1.39B $1.81B $1.89B $1.43B $981M $625M $280M $42M $289M $165M $11M $-139M
Treasury Stock 12-point trend, -100.0% $0 $0 $0 $0 $0 $0 $0 $55.0K $1.66B $1.55B $1.54B $1.42B
AOCI 12-point trend, -131.4% $-172M $-317M $-196M $-262M $-165M $-139M $-178M $-173M $-145M $-254M $-136M $-74M
Stockholders' Equity 12-point trend, +370.8% $3.16B $3.46B $3.60B $2.98B $2.53B $2.11B $1.63B $1.32B $1.05B $837M $733M $672M
Liabilities + Equity 12-point trend, +281.5% $7.14B $7.53B $8.20B $7.60B $7.02B $5.49B $4.69B $3.86B $2.93B $2.71B $2.07B $1.87B
Shares Outstanding 12-point trend, +4.0% 49,217,000 51,141,000 51,338,000 50,944,000 50,480,000 49,767,000 48,936,000 48,209,000 47,402,000 47,363,000 46,698,000 47,327,000
キャッシュフロー 18
CRLの年次キャッシュフローデータ
指標 トレンド 202520242023202220212020201920182017201620152014
D&A 12-point trend, +318.2% $403M $362M $314M $304M $266M $235M $198M $162M $131M $127M $95M $96M
Stock-based Comp 12-point trend, +129.0% $71M $70M $72M $74M $71M $56M $57M $47M $44M $44M $40M $31M
Deferred Tax 12-point trend, -953.7% $-75M $-67M $-51M $-33M $-20M $2M $-21M $-10M $28M $3M $4M $9M
Amort. of Intangibles 12-point trend, +589.9% $179M $138M $137M $147M $125M $112M $90M $65M $41M $42M $24M $26M
Restructuring 12-point trend, +1181.0% $100M $107M $30M $8M $7M $13M $14M $10M $5M $18M $8M $8M
Other Non-cash 11-point trend, +122367.8% $483M $348M $-126M $-211M $53M $-111M $-5M $16M $-8M $-28M $-395.0K ·
Operating Cash Flow 12-point trend, +192.6% $738M $735M $684M $620M $761M $547M $481M $441M $318M $317M $307M $252M
CapEx 12-point trend, +285.0% $219M $233M $319M $325M $229M $167M $141M $140M $82M $55M $63M $57M
Investing Cash Flow 10-point trend, +69.8% $-209M $-245M $-563M $-608M $-1.44B $-602M $-682M $-955M $-73M $-693M · ·
Debt Issued 10-point trend, +17.5% $1.23B $1.08B $776M $2.95B $6.95B $2.23B $3.36B $2.76B $237M $1.04B · ·
Net Debt Issued 8-point trend, -55.4% $1.23B $1.08B $776M $2.95B $6.95B $2.23B $3.36B $2.76B · · · ·
Stock Repurchased 12-point trend, +195.6% $361M $119M $24M $39M $41M $24M $18M $14M $107M $12M $117M $122M
Net Stock Activity 12-point trend, -195.6% $-361M $-119M $-24M $-39M $-41M $-24M $-18M $-14M $-107M $-12M $-117M $-122M
Financing Cash Flow 10-point trend, -241.0% $-537M $-551M $-86M $-42M $673M $47M $232M $558M $-208M $381M · ·
Net Change in Cash 12-point trend, +154.6% $10M $-79M $43M $-5M $13M $-7M $43M $31M $46M $-69.0K $-43M $4M
Taxes Paid 8-point trend, +77.0% $120M $126M $90M $76M $75M $60M $54M $68M · · · ·
Free Cash Flow 12-point trend, +165.6% $518M $502M $365M $295M $532M $380M $340M $301M $236M $245M $225M $195M
Levered FCF 10-point trend, +35.4% · · $252M $248M $471M $309M $290M $250M $223M $226M $213M $186M
収益性 7
CRLの年次収益性データ
指標 トレンド 202520242023202220212020201920182017201620152014
Operating Margin 12-point trend, -95.4% 0.63% 5.6% 14.9% 16.4% 16.7% 14.8% 13.4% 14.6% 15.5% 14.1% 15.1% 13.7%
Net Margin 11-point trend, -132.8% -3.6% 0.55% 11.5% 12.2% 11.0% 12.5% 9.6% 10.0% 6.6% 9.2% 10.9% ·
Pretax Margin 12-point trend, -118.1% -2.5% 2.3% 14.1% 15.7% 13.6% 15.3% 11.6% 12.4% 16.0% 13.3% 14.3% 13.7%
EBITDA Margin 12-point trend, -49.5% 10.7% 14.5% 22.6% 24.0% 24.2% 22.8% 20.9% 21.8% 22.5% 21.6% 22.1% 21.1%
ROA 11-point trend, -126.0% -2.0% 0.28% 6.0% 6.7% 6.2% 7.1% 5.9% 6.7% 4.4% 6.5% 7.6% ·
ROE 11-point trend, -120.5% -4.4% 0.63% 14.4% 17.6% 16.8% 19.4% 17.1% 19.2% 13.1% 19.7% 21.2% ·
ROIC 12-point trend, -87.5% 1.1% 1.8% 14.2% 17.3% 19.3% 16.4% 17.6% 9.0% 5.6% 8.1% 10.2% 9.1%
流動性と支払能力 5
CRLの年次流動性と支払能力データ
指標 トレンド 202520242023202220212020201920182017201620152014
Current Ratio 12-point trend, -37.0% 1.3 1.4 1.5 1.3 1.2 1.4 1.4 1.6 1.8 1.5 1.8 2.0
Quick Ratio 12-point trend, -41.7% 0.8 0.9 1.0 0.9 0.9 1.0 1.1 1.2 1.3 1.1 1.2 1.4
Debt / Equity 12-point trend, -100.0% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.1 1.4 1.1 1.1
LT Debt / Equity 5-point trend, +15.0% · · · · · · · 1.2 1.0 1.4 1.1 1.1
Interest Coverage 10-point trend, -69.6% · · 4.5 11.0 8.0 5.0 5.8 5.2 9.7 8.6 13.7 14.9
効率性 3
CRLの年次効率性データ
指標 トレンド 202520242023202220212020201920182017201620152014
Asset Turnover 12-point trend, -25.8% 0.5 0.5 0.5 0.5 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.7
Inventory Turnover 4-point trend, -8.0% · · · · · · · · 2.7 2.9 2.9 3.0
Receivables Turnover 12-point trend, +3.6% 5.6 5.4 5.4 5.7 5.6 5.2 5.3 5.0 4.7 5.3 5.2 5.4
1株あたり 5
CRLの年次1株あたりデータ
指標 トレンド 202520242023202220212020201920182017201620152014
Book Value / Share 12-point trend, +352.7% $64.30 $67.69 $70.06 $58.42 $50.21 $42.49 $33.40 $27.33 $22.05 $17.67 $15.70 $14.20
Revenue / Share 10-point trend, +131.1% $81.01 $78.45 $80.26 $77.50 $68.84 $57.77 $52.75 $46.23 $38.25 $35.06 · ·
Cash Flow / Share 10-point trend, +137.6% $14.88 $14.23 $13.29 $12.08 $14.79 $10.80 $9.68 $9.00 $6.55 $6.26 · ·
Cash / Share 12-point trend, +28.5% $4.34 $3.81 $5.39 $4.59 $4.78 $4.59 $4.86 $4.05 $3.46 $2.48 $2.53 $3.38
EPS (TTM) 12-point trend, -209.4% $-2.91 $0.20 $9.22 $9.48 $7.60 $7.20 $5.07 $4.62 $2.54 $3.23 $3.13 $2.66
成長率 7
CRLの年次成長率データ
指標 トレンド 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -104.0% -0.85% -1.9% 3.9% 12.3% 21.1% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -97.3% 0.33% 4.6% 12.2% · · · · · · · · ·
Revenue CAGR 5Y 6.6% · · · · · · · · · · ·
EPS YoY 4-point trend, -1859.5% · -97.8% -2.7% 24.7% 5.6% · · · · · · ·
EPS CAGR 3Y 2-point trend, -917.9% · -70.3% 8.6% · · · · · · · · ·
Net Income YoY 4-point trend, -1402.2% · -95.3% -2.4% 24.4% 7.3% · · · · · · ·
Net Income CAGR 3Y 2-point trend, -767.7% · -61.6% 9.2% · · · · · · · · ·
バリュエーション(TTM) 14
CRLの年次バリュエーション(TTM)データ
指標 トレンド 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +209.4% $4.02B $4.05B $4.13B $3.98B $3.54B $2.92B $2.62B $2.27B $1.86B $1.68B $1.36B $1.30B
Net Income TTM 12-point trend, -213.9% $-144M $22M $475M $486M $391M $364M $252M $226M $123M $155M $149M $127M
Market Cap 12-point trend, +229.4% $10.02B $9.52B $12.14B $11.10B $18.64B $12.53B $7.43B $5.39B $5.19B $3.61B $3.74B $3.04B
Enterprise Value 12-point trend, +169.8% $9.81B $9.33B $11.86B $10.87B $18.40B $12.34B $7.23B $6.84B $6.12B $4.70B $4.46B $3.64B
P/E 12-point trend, -389.6% -70.0 930.8 25.6 23.0 48.6 35.0 30.0 24.2 43.1 23.6 25.6 24.2
P/S 12-point trend, +6.5% 2.5 2.4 2.9 2.8 5.3 4.3 2.8 2.4 2.8 2.1 2.7 2.3
P/B 12-point trend, -30.0% 3.2 2.8 3.4 3.7 7.4 5.9 4.5 4.1 5.0 4.3 5.1 4.5
P / Tangible Book 166.0 · · · · · · · · · · ·
P / Cash Flow 12-point trend, +12.6% 13.6 13.0 17.7 17.9 24.5 22.9 15.5 12.2 16.3 12.0 13.0 12.1
P / FCF 12-point trend, +24.0% 19.3 19.0 33.2 37.6 35.0 33.0 21.8 17.9 22.0 14.7 16.6 15.6
EV / EBITDA 12-point trend, +72.6% 22.9 15.8 12.7 11.4 21.5 18.5 13.2 13.9 14.6 12.9 14.8 13.3
EV / FCF 12-point trend, +1.6% 18.9 18.6 32.5 36.9 34.6 32.5 21.2 22.7 26.0 19.2 19.8 18.6
EV / Revenue 12-point trend, -12.8% 2.4 2.3 2.9 2.7 5.2 4.2 2.8 3.0 3.3 2.8 3.3 2.8
Earnings Yield 12-point trend, -134.5% -1.4% 0.11% 3.9% 4.3% 2.1% 2.9% 3.3% 4.1% 2.3% 4.2% 3.9% 4.1%

財務諸表 損益計算書、貸借対照表、キャッシュフロー — 年次、過去5年間

損益計算書
2025-12-272024-12-282023-12-302022-12-312021-12-25
収益 $4.02B$4.05B$4.13B$3.98B$3.54B
営業利益率 % 0.63%5.6%14.9%16.4%16.7%
純利益 $-144M$22M$475M$486M$391M
希薄化後EPS $-2.91$0.20$9.22$9.48$7.60
貸借対照表
2025-12-272024-12-282023-12-302022-12-312021-12-25
負債資本倍率 0.00.00.00.00.0
流動比率 1.31.41.51.31.2
クイックレシオ 0.80.91.00.90.9
キャッシュフロー
2025-12-272024-12-282023-12-302022-12-312021-12-25
フリーキャッシュフロー $518M$502M$365M$295M$532M

最新ニュース この会社に言及した最近の見出し

マイ指標 あなた専用のウォッチリスト — 決算詳細から選択した行

📊

あなたにとって重要なメトリクスを選択 — 上記の決算詳細の任意の行の横にある➕をクリックしてください。

選択内容は保存され、すべてのティッカーで引き継がれます。

機関投資家(13F) 616 提出者 · $7.8B合計 · 時点 2026年6月30日

四半期SECフォーム13Fでこの株式の保有を報告している機関。ロングポジションのみ。単一の提出者は、別々のオプションレッグで2回表示される場合があります。 大きな反対売買のプット/コール・レッグは、通常、マーケットメイクまたはヘッジされた在庫を反映しており、方向性への確信を示すものではありません。

機関投資家の動向 — Q2 2026 対 前四半期
新規ポジション 解消済みポジション 増加 減少 純株式数増減
82 (-1 前期比) 59 (-23 前期比) 180 (-11 前期比) 201 (+15 前期比) +5.0M

Q1 2026と比較しました。 SECフォーム13Fの提出期限は四半期末から45日後ですが、遅延提出者向けの短いバッファーが含まれます。この期間内の四半期は、直近で完全に報告されたペアを優先するためスキップされます。

機関投資家 評価額 株式数 % 追跡された13Fのうち タイプ
FMR LLC $737,350,307 3,251,247 9.42% 株式数
VANGUARD CAPITAL MANAGEMENT LLC $714,227,026 3,149,288 9.12% 株式数
HARRIS ASSOCIATES L P $508,269,048 2,241,144 6.49% 株式数
VANGUARD PORTFOLIO MANAGEMENT LLC $501,427,927 2,210,979 6.40% 株式数
STATE STREET CORP $422,800,968 1,864,284 5.40% 株式数
DIMENSIONAL FUND ADVISORS LP $348,883,077 1,538,354 4.46% 株式数
CITADEL ADVISORS LLC $270,696,771 1,193,601 3.46% 株式数
GEODE CAPITAL MANAGEMENT, LLC $259,130,041 1,144,937 3.31% 株式数
EARNEST PARTNERS LLC $254,007,295 1,120,011 3.24% 株式数
WELLINGTON MANAGEMENT GROUP LLP $223,361,616 984,883 2.85% 株式数
AMERIPRISE FINANCIAL INC $192,886,814 850,503 2.46% 株式数
NEUBERGER BERMAN GROUP LLC $192,182,793 847,488 2.45% 株式数
Clearbridge Investments, LLC $177,185,527 781,276 2.26% 株式数
COOKE & BIELER LP $171,369,328 755,630 2.19% 株式数
VICTORY CAPITAL MANAGEMENT INC $150,762,735 664,768 1.93% 株式数
MILLENNIUM MANAGEMENT LLC $110,324,717 486,462 1.41% 株式数
BANK OF AMERICA CORP /DE/ $104,921,899 462,639 1.34% 株式数
Gotham Asset Management, LLC $98,233,181 433,146 1.25% 株式数
Amundi $93,528,650 412,402 1.19% 株式数
NORGES BANK $83,921,372 370,040 1.07% 株式数
MARSHALL WACE, LLP $76,947,125 339,288 0.98% 株式数
Iron Triangle Partners LP $75,748,141 379,728 0.97% 株式数
ALLIANCEBERNSTEIN L.P. $64,615,913 374,585 0.83% 株式数
SNYDER CAPITAL MANAGEMENT L P $63,899,443 281,756 0.82% 株式数
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP $63,174,169 278,558 0.81% 株式数
BNP PARIBAS FINANCIAL MARKETS $63,095,473 278,211 0.81% 株式数
VANGUARD FIDUCIARY TRUST CO $61,384,115 270,665 0.78% 株式数
PRIMECAP MANAGEMENT CO/CA/ $60,523,448 266,870 0.77% 株式数
GOLDMAN SACHS GROUP INC $57,319,812 252,744 0.73% 株式数
Meridiem Capital Partners LP $56,012,367 246,979 0.72% 株式数
Alyeska Investment Group, L.P. $53,295,650 235,000 0.68% 株式数
Quantinno Capital Management LP $49,020,824 216,150 0.63% 株式数
ADAGE CAPITAL PARTNERS GP, L.L.C. $48,415,129 213,480 0.62% 株式数
Boston Trust Walden Corp $46,506,918 205,066 0.59% 株式数
Burgundy Asset Management Ltd. $45,453,909 278,329 0.58% 株式数
SRS Investment Management, LLC $42,496,817 187,384 0.54% 株式数
LOOMIS SAYLES & CO L P $38,517,487 169,838 0.49% 株式数
JONES FINANCIAL COMPANIES LLLP $37,184,513 172,350 0.47% 株式数
PERCEPTIVE ADVISORS LLC $31,750,600 140,000 0.41% 株式数
LAKEWOOD CAPITAL MANAGEMENT, LP $30,389,860 134,000 0.39% 株式数
NEW YORK STATE COMMON RETIREMENT FUND $29,879,583 131,750 0.38% 株式数
BlackRock, Inc. $29,025,945 127,986 0.37% 株式数
PICTON MAHONEY ASSET MANAGEMENT $26,340,305 116,144 0.34% 株式数
FIL Ltd $25,184,576 111,048 0.32% 株式数
Candriam S.C.A. $23,824,478 105,152 0.30% 株式数
Clark Capital Management Group, Inc. $23,010,567 101,462 0.29% 株式数
Vanguard Global Advisers, LLC $22,453,344 99,005 0.29% 株式数
Swiss National Bank $22,452,210 99,000 0.29% 株式数
CONFLUENCE INVESTMENT MANAGEMENT LLC $20,491,384 90,354 0.26% 株式数
ENVESTNET ASSET MANAGEMENT INC $20,280,546 89,424 0.26% 株式数
SUSQUEHANNA INTERNATIONAL GROUP, LLP $19,730,730 87,000 0.25% コールオプション
NOMURA HOLDINGS INC $19,672,672 86,744 0.25% 株式数
RHUMBLINE ADVISERS $19,484,825 85,916 0.25% 株式数
Ilex Capital Partners (UK) LLP $18,413,760 81,193 0.24% 株式数
Aristotle Capital Boston, LLC $18,273,438 80,574 0.23% 株式数
CITADEL ADVISORS LLC $17,485,509 77,100 0.22% コールオプション
NICHOLAS COMPANY, INC. $16,305,067 71,895 0.21% 株式数
MANUFACTURERS LIFE INSURANCE COMPANY, THE $15,172,024 66,899 0.19% 株式数
Mitsubishi UFJ Asset Management Co., Ltd. $15,164,087 66,864 0.19% 株式数
Ranger Investment Management, L.P. $15,009,416 66,182 0.19% 株式数
California Public Employees Retirement System $14,670,818 64,689 0.19% 株式数
Assenagon Asset Management S.A. $14,020,385 61,821 0.18% 株式数
ASSETMARK, INC $13,939,194 61,463 0.18% 株式数
Rhenman & Partners Asset Management AB $12,972,388 57,200 0.17% 株式数
RIVERBRIDGE PARTNERS LLC $12,859,587 56,703 0.16% 株式数
TD Asset Management Inc $12,854,230 56,679 0.16% 株式数
SUSQUEHANNA INTERNATIONAL GROUP, LLP $12,836,314 56,600 0.16% プットオプション
Laurus Investment Counsel Inc. $12,365,663 71,685 0.16% 株式数
KING LUTHER CAPITAL MANAGEMENT CORP $12,204,023 53,812 0.16% 株式数
FRONTIER CAPITAL MANAGEMENT CO LLC $11,552,133 50,938 0.15% 株式数
Universal- Beteiligungs- und Servicegesellschaft mbH $10,732,081 47,278 0.14% 株式数
RAYMOND JAMES FINANCIAL INC $10,506,727 46,328 0.13% 株式数
VANGUARD ASSET MANAGEMENT, Ltd $10,472,482 46,177 0.13% 株式数
KENNEDY CAPITAL MANAGEMENT LLC $9,914,950 43,719 0.13% 株式数
BARCLAYS PLC $9,909,816 43,696 0.13% 株式数
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $9,827,670 56,972 0.13% 株式数
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $9,382,529 41,371 0.12% 株式数
Park West Asset Management LLC $9,343,748 41,200 0.12% 株式数
State of Tennessee, Department of Treasury $8,457,000 37,290 0.11% 株式数
J.P. Marvel Investment Advisors, LLC $8,456,092 37,286 0.11% 株式数
CASTLEARK MANAGEMENT LLC $8,174,646 36,045 0.10% 株式数
JANE STREET GROUP, LLC $7,869,613 34,700 0.10% コールオプション
Pine Ridge Advisers LLC $7,710,860 34,000 0.10% 株式数
PRUDENTIAL FINANCIAL INC $7,346,635 32,394 0.09% 株式数
Capricorn Fund Managers Ltd $7,092,630 31,274 0.09% 株式数
STATE OF WISCONSIN INVESTMENT BOARD $7,000,554 30,868 0.09% 株式数
FIRST TRUST ADVISORS LP $6,951,290 30,651 0.09% 株式数
Caption Management, LLC $6,803,700 30,000 0.09% プットオプション
Engineers Gate Manager LP $6,637,463 29,267 0.08% 株式数
LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE $6,351,027 28,004 0.08% 株式数
Midwest Trust Co $6,091,126 26,858 0.08% 株式数
VAN ECK ASSOCIATES CORP $5,942,578 26,203 0.08% 株式数
SEI INVESTMENTS CO $5,929,630 26,150 0.08% 株式数
Sendero Wealth Management, LLC $5,909,468 26,057 0.08% 株式数
13D Management LLC $5,851,182 25,800 0.07% 株式数
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $5,500,853 31,889 0.07% 株式数
D. E. Shaw & Co., Inc. $5,462,691 24,087 0.07% 株式数
INVESTMENT HOUSE LLC $5,447,042 24,018 0.07% 株式数
LPL Financial LLC $5,409,169 23,851 0.07% 株式数
LRT Capital Management, LLC $5,348,842 23,585 0.07% 株式数

企業インサイダー 57 人のインサイダー · 21人の役員 · 27人の取締役

インサイダー 役職 最終アクティビティ 保有株式数 12ヶ月購入 12ヶ月売却 12ヶ月純額
Glenn Coleman EVP & Chief Financial Officer 2026年5月29日 A 27,752 0 0 $0
Flavia Pease Corporate Executive VP & CFO 2025年5月31日 F 17,297 0 0 $0
David Ross Smith Corporate Executive VP & CFO 2022年3月3日 M 25,819 0 0 $0
Davide Molho President & COO 2018年7月24日 M 17,155 0 0 $0
Mark Mintz EVP, Chief Information Officer 2026年5月31日 F 9,546 0 0 $0
William D Barbo Corporate Executive VP & CCO 2024年11月7日 G 23,337 0 0 $0
John W Kuo CEVP General Counsel & CCO 2020年6月1日 A 3,171 0 0 $0
David P Johst Corporate Executive VP 2020年5月29日 A 224,478 0 0 $0
John J Crowley SVP, Chief Accounting Officer 2016年10月1日 F 5,599 0 0 $0
Nancy Gillett Corporate Executive VP 2016年3月2日 S 11,034 0 0 $0
Jorg Geller Corporate Executive VP 2015年2月25日 M 14,094 0 0 $0
RENAUD REAL H Corp. Executive VP 2010年8月11日 F 74,390 0 0 $0
Christopher Berthoux Executive Vice President 2010年2月26日 A 31,897 0 0 $0
Joanne P Acford Corp. Sr VP, GC and Corp. Sec 2007年8月11日 F 37,109 0 0 $0
David J Elliott Officer 2007年6月29日 M 11,750 0 0 $0
Cheri L Walker Corporate Senior VP 2007年5月1日 A 6,262 0 0 $0
Stephanie B Wells Senior Vice President 2007年4月2日 A 11,500 0 0 $0
Nicholas Ventresca Senior Vice President 2007年4月2日 F 12,713 0 0 $0
John C Ho Senior Vice President 2007年2月23日 A 12,710 0 0 $0
Brian Bathgate Corporate Vice President 2006年2月27日 S 16,134 0 0 $0
Alastair Stuart Mcewan Corporate VP 2004年12月23日 M 8,000 0 0 $0
Steven Barg 取締役 2026年6月2日 A 3,287 0 0 $0
Nancy C Andrews 取締役 2026年5月12日 G 3,964 0 0 $0
Reshema Kemps-Polanco 取締役 2026年5月8日 A 4,563 0 0 $0
George Llado 取締役 2026年5月8日 A 6,702 0 0 $0
Abraham Ceesay 取締役 2026年5月8日 A 2,384 0 0 $0
Mark J Enyedy 取締役 2026年5月8日 A 2,384 0 0 $0
Paul W Graves 取締役 2026年5月8日 A 2,384 0 0 $0
Craig B. Thompson 取締役 2026年5月8日 A 3,851 0 0 $0
Martin Mackay 取締役 2026年5月8日 A 17,137 0 0 $0
Virginia M Wilson 取締役 2026年5月8日 A 6,349 0 0 $0
George Massaro 取締役 2025年5月15日 S 5,575 0 0 $0
Richard F Wallman 取締役 2024年11月7日 S 0 0 0 $0
Deborah Turner Kochevar 取締役 2024年5月13日 A 7,894 0 0 $0
Robert J Bertolini 取締役 2024年5月13日 A 32,802 0 0 $0
Richard C Reese 取締役 2023年5月15日 A 65,541 0 0 $0
George M Milne JR 取締役 2021年5月7日 A 29,079 0 0 $0
Stephen D Chubb 取締役 2021年2月23日 M 40,529 0 0 $0
Jean-Paul Mangeolle 取締役 2019年5月22日 A 3,886 0 0 $0
William Waltrip 取締役 2012年12月5日 S 21,830 0 0 $0
Samuel O Thier MD 取締役 2012年5月9日 A 18,230 0 0 $0
Douglas E Rogers 取締役 2010年5月7日 A 12,859 0 0 $0
Nancy T Chang 取締役 2010年5月7日 A 31,010 0 0 $0
Linda Mcgoldrick 取締役 2006年2月13日 A 0 0 $0
Walter S Nimmo 取締役 2005年2月25日 S 149,447 0 0 $0
John Urquhart 取締役 2005年2月17日 A 11,738 0 0 $0
Louise S Mccrary 取締役 2005年2月17日 A 0 0 $0
Robert Cawthorn 取締役 2004年6月2日 G 278,600 0 0 $0
Shannon M Parisotto 2026年8月11日 M 4,807 0 2 $-2,365,755
Birgit Girshick 2026年8月11日 M 36,013 0 1 $-1,819,350

SECフォーム3/4/5提出書類からのインサイダー;純額=公開市場のP/Sのみ

アクティビストおよび5%超のオーナー 6保有

SECスケジュール13Dを提出した投資家 — 発行体の影響を与える意図(アクティビストの保有、取締役会キャンペーン、M&A)を持つ5%超の受益権所有。各行は、その提出者のポジションの最新の既知の状態を示します。

提出者 提出済み 保有 ステータス 目的 提出書類
JANA PARTNERS LLC ×4 提出書類 2011年8月4日 初回提出 SEC
Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 提出書類 2011年2月9日 初回提出 SEC
Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 提出書類 2010年12月7日 初回提出 SEC
未開示の報告者 2010年6月16日 初回提出 SEC
未開示の報告者 2010年6月7日 初回提出 受動的投資 SEC
Charles River Laboratories International, Inc. IRS No. 061397316 2010年5月5日 初回提出 取締役会キャンペーン SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF保有状況 135のETFが保有

ウェイトは直接株式保有(N-PORT)のみを反映しています。レバレッジ型またはデリバティブベースのファンドは、表示されていない追加のスワップエクスポージャーを保有している可能性があります。

ファンド ウェイト 単位 時点 ソース
RSPH · Invesco Exchange-Traded Fund Trust 2.18% 63,652 SH 2026年8月8日 日次
HTEC · EXCHANGE TRADED CONCEPTS TRUST 1.49% 4,749 NS 2026年4月30日 N-PORT
EPSB · Harbor ETF Trust 1.33% 370 NS 2026年4月30日 N-PORT
SPHB · Invesco Exchange-Traded Fund Trust … 1.18% 41,597 SH 2026年8月8日 日次
EPMV · Harbor ETF Trust 1.09% 291 NS 2026年4月30日 N-PORT
IBB · iShares Trust 0.97% 349,491 SH 2026年8月8日 日次
EPSV · Harbor ETF Trust 0.90% 270 NS 2026年4月30日 N-PORT
TAX · EA Series Trust 0.80% 1,131 NS 2026年5月29日 N-PORT
LSEQ · Harbor ETF Trust 0.66% 612 NS 2026年4月30日 N-PORT
HIBL · Direxion Shares ETF Trust 0.50% 2,356 NS 2026年4月30日 N-PORT
ISCV · iShares Trust 0.40% 10,497 SH 2026年8月8日 日次
FNY · First Trust Exchange-Traded AlphaDE… 0.38% 11,925 NS 2026年4月30日 N-PORT
PKW · Invesco Exchange-Traded Fund Trust 0.38% 25,401 SH 2026年8月8日 日次
VGHY · VANGUARD FIXED INCOME SECURITIES FU… 0.36% 1,145,000 PA 2026年8月8日 日次
IQSM · New York Life Investments ETF Trust 0.33% 6,161 NS 2026年4月30日 N-PORT
FFSM · FIDELITY COVINGTON TRUST 0.29% 22,440 NS 2026年4月30日 N-PORT
RSP · Invesco Exchange-Traded Fund Trust 0.27% 996,151 SH 2026年8月8日 日次
DFAT · Dimensional ETF Trust 0.26% 212,321 NS 2026年4月30日 N-PORT
VBR · VANGUARD INDEX FUNDS 0.23% 701,498 SH 2026年8月8日 日次
ESML · iShares Trust 0.23% 24,979 SH 2026年8月8日 日次
BKMC · BNY Mellon ETF Trust 0.22% 8,115 NS 2026年4月30日 N-PORT
IYH · iShares Trust 0.21% 29,370 SH 2026年8月8日 日次
ISCB · iShares Trust 0.20% 2,125 SH 2026年8月8日 日次
SMMD · iShares Trust 0.17% 24,455 SH 2026年8月8日 日次
FSMD · FIDELITY COVINGTON TRUST 0.17% 24,528 NS 2026年4月30日 N-PORT
SCHM · SCHWAB STRATEGIC TRUST 0.17% 133,341 NS 2026年5月31日 N-PORT
DFAS · Dimensional ETF Trust 0.16% 138,243 NS 2026年4月30日 N-PORT
IXJ · iShares Trust 0.16% 25,598 SH 2026年8月8日 日次
VHT · VANGUARD WORLD FUND 0.16% 148,331 SH 2026年8月8日 日次
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0.15% 18,369 NS 2026年4月30日 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.15% 6,079 NS 2026年5月31日 N-PORT
WSML · iShares Trust 0.13% 6,018 SH 2026年8月8日 日次
FHLC · FIDELITY COVINGTON TRUST 0.13% 22,674 NS 2026年4月30日 N-PORT
DFSV · Dimensional ETF Trust 0.13% 59,338 NS 2026年4月30日 N-PORT
VB · VANGUARD INDEX FUNDS 0.13% 1,102,914 SH 2026年8月8日 日次
VGMS · VANGUARD MALVERN FUNDS 0.13% 315,000 PA 2026年8月8日 日次
EQAL · Invesco Exchange-Traded Fund Trust … 0.13% 4,072 SH 2026年8月8日 日次
RXL · ProShares Trust 0.13% 513 NS 2026年5月31日 N-PORT
IWS · iShares Trust 0.13% 74,284 SH 2026年8月8日 日次
REVS · Columbia ETF Trust I 0.12% 2,082 NS 2026年4月30日 N-PORT
CURE · Direxion Shares ETF Trust 0.12% 982 NS 2026年4月30日 N-PORT
SMLF · iShares Trust 0.12% 18,532 SH 2026年8月8日 日次
FAD · First Trust Exchange-Traded AlphaDE… 0.11% 3,280 NS 2026年4月30日 N-PORT
FBCV · FIDELITY COVINGTON TRUST 0.11% 1,032 NS 2026年4月30日 N-PORT
IWR · iShares Trust 0.09% 199,595 SH 2026年8月8日 日次
AVMC · AMERICAN CENTURY ETF TRUST 0.09% 1,986 NS 2026年5月31日 N-PORT
IEUS · iShares Trust 0.09% 4,951 SH 2026年8月8日 日次
XOEF · iShares Trust 0.07% 61 SH 2026年8月8日 日次
VSDB · VANGUARD MALVERN FUNDS 0.07% 635,000 PA 2026年8月8日 日次
FNX · First Trust Exchange-Traded AlphaDE… 0.07% 5,261 NS 2026年4月30日 N-PORT